Clinical analysis of imatinib mesylate in the treatment of chronic myeloid leukemia / 中国基层医药

ABSTRACT

Objective To study and explore the clinical effect of imatinib mesylate in the treatment of chronic myeloid leukemia. Methods From January 2013 to January 2017,60 patients with chronic myeloid leukemia in the Second Hospital of Jiaxing were included in the study. The patients were randomly divided into control group and observation group,with 30 cases in each group. The control group was given routine chemotherapy, the observation group was given routine chemotherapy combined wth imatinib mesylate orally. After 6 months of treatment,the clinical curative effect, the incidence of adverse reactions, immune function, quality of life score of the two groups were compared. Results The response rate of the observation group was 76. 67％ (23/30),which was higher than 50. 00％(15/30) of the control group (χ2 =4. 593,P <0. 05). The incidence rate of adverse reactions in the observation group was 13. 33％(4/30),which was significantly lower than 36. 67％(11/30) in the control group (χ2 =4. 356,P<0. 05). Before treatment,the immune function indicators between the two groups had no statistically significant differences (t=0. 168,0. 287,0. 156,all P>0. 05). After treatment,the indicators of immune function in the observation group were higher than those in the control group(t =4. 482,3. 731,3. 361,all P <0. 05). After treatment,the quality of life scores in the observation group were higher than those in the control group( t=8. 898, 5. 945,9. 309,5. 679,all P<0. 05). Conclusion Imatinib mesylate in the treatment of patients with chronic myelog-enous leukemia can effectively improve the efficacy and safety of chemotherapy,reduce the effect of chemotherapy on the immune function of patients,improve their quality of life.